EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy programme for epilepsy ahead of first-in-human trial

PartnershipEPY201Positive

AI Analysis

Summary

EpilepsyGTx announced a collaboration with Viralgen, an AAV-specialist CDMO, to support scalable production of EPY201 for focal refractory epilepsy ahead of first-in-human trials. The partnership aims to enable clinical development of the gene therapy targeting a condition affecting approximately 10 million people.

Clinical Trial Data

Phase

first-in-human

Outcome Details

Collaboration agreement with AAV-specialist CDMO for scalable production

Importance:6/10

Sentiment:

0.60

gene therapyAAVepilepsyCDMO partnershipmanufacturingrare disease

Related Companies

$TRAX

Read the original article

Published by PR Newswire Clinical Trials on September 9, 2026 8:00 AM

Read Original